Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer.
Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer.
复制标题
循环外泌体 miR-125a-3p 作为早期结肠癌的新型生物标志物
DOI：
10.1038/s41598-017-04386-1
复制
发表时间：
2017-06-23
影响因子：
4.6
通讯作者：
Huang X
中科院分区：
文献类型：
--
作者：
Wang J;Yan F;Zhao Q;Zhan F;Wang R;Wang L;Zhang Y;Huang X
循环外切体作为人类肿瘤诊断和预后的生物标志物具有很大的潜力。在此之前，我们已经应用小RNA测序来确定异常表达的外体miRNAs作为结肠癌患者诊断标记物的候选。在这个验证队列中，从50名早期结肠癌患者和50名匹配的健康志愿者中提取了血浆来源的外体miRNA。实时荧光定量聚合酶链式反应显示miR-125A-3P、miR-320C在早期结肠癌患者血浆外切体中表达显著上调。ROC曲线显示miR-125a-3p丰富水平预测结肠癌的曲线下面积(AUC)为68.5%，而CEA为83.6%。MiR-125A-3P与CEA联合应用可使AUC提高到85.5%。此外，血浆中miR-125a-3p和miR-320C的外切体水平与神经侵袭显著相关(P <； )，而与肿瘤大小、侵袭深度和分化程度无关(P >； )。血浆癌胚抗原水平与肿瘤大小、浸润深度、分化程度呈正相关(P <； 0.3009~0.7270)，与神经浸润无关(P = 0.744)。总之，这项随访研究表明，循环血浆外体miR-125a-3p很容易作为早期结肠癌的诊断生物标志物。MiR-125a-3p与常规诊断标记物联合应用可提高诊断能力。
Circulating exosome holds great potentials as biomarker for diagnosis and prognosis of human cancers. Previously, we have applied small RNA sequencing to identify aberrantly expressed exosomal miRNAs as candidates for diagnostic markers in colon cancer patients. In this validation cohort, plasma derived exosomal miRNA was isolated from 50 early-stage colon cancer patients and 50 matched healthy volunteers. Real-time qRT-PCR revealed that miR-125a-3p, miR-320c were significantly up-regulated in plasma exosomes of the patients with early stage colon cancer. ROC curve showed that miR-125a-3p abundant level may predict colon cancer with an area of under the curve (AUC) of 68.5%, in comparison to that of CEA at 83.6%. Combination of miR-125a-3P and CEA improved the AUC to 85.5%. In addition, plasma exosome level of miR-125a-3p and miR-320c showed significant correlation with nerve infiltration (P < 0.01), but not with tumor size, infiltration depth, and differentiation degree (P > 0.05). On the contrary, plasma CEA level is correlated with tumor size, infiltration depth, and differentiation degree (P < 0.05, r = 0.3009–0.7270), but not with nerve infiltration (P = 0.744). In conclusion, this follow-up study demonstrated circulating plasma exosomal miR-125a-3p is readily accessible as diagnosis biomarker for early-stage colon cancer. When combined with conventional diagnostic markers, miR-125a-3p can improve the diagnostic power.